glp·helper
glphelper.com/wegovy/california/redondo-beach
GLP-1 receptor agonistFDA-approved June 2021Rx · Subcutaneous injection · Once weekly

Wegovy® providers &
prescriptions in Redondo Beach, CA

Verified Wegovy providers in Redondo Beach, CA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Wegovy weight loss →trial-anchored estimate
city providers
30
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: California
31 of 31 shown

Find an Wegovy provider in California.

Every entry is checked against the NPI registry and the California medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by California city · /wegovy/california/{city}
§ 03Getting Wegovy in Redondo Beach
31 providers · Redondo Beach, CA

How to get Wegovy in Redondo Beach.

31 GLP-1 prescribers and 7 local resource types are on record for Redondo Beach, plus 3 nearby towns in the directory.

Prescribers in Redondo Beach
31 prescribers
31 GLP-1 prescribers in Redondo Beach, most listed as Family Medicine (13), Internal Medicine (12) and Internal Medicine, Endocrinology, Diabetes & Metabolism (5). Any California-licensed physician, nurse practitioner, or PA can prescribe Wegovy, over video or in person. The nearest towns on record are Torrance (36 providers), Lawndale (18 providers) and Manhattan Beach (32 providers).
Around the prescription in Redondo Beach
7 listed nearby
30 dietitians, 7 nutritionists, 6 gyms, 6 fitness clubs, 5 trainers, 6 physiotherapists and 4 places to move are on record near Redondo Beach.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Ozempic, higher dose.

Wegovy is the brand name for semaglutide at the higher 2.4 mg dose. It is the same molecule as Ozempic, marketed by the same manufacturer for a different FDA-approved indication. It is a once-weekly subcutaneous injection in the GLP-1 receptor agonist class.[2][3]

In the STEP-1 randomized trial, 68 weeks of weekly 2.4 mg semaglutide produced a mean body-weight reduction of 14.9%, roughly 2.5× the weight loss seen at the Ozempic 1 mg dose. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity such as hypertension or dyslipidemia.[1]

At a glanceNDC 0169-4525
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
June 2021
Approved use
Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Off-label use
Off-label use is uncommon. Ozempic is the FDA-approved formulation for type 2 diabetes
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Redondo Beach

Redondo Beach, California has a population of 71,576 people. The adult obesity rate in Redondo Beach is an age-adjusted estimate of 21.2%, 7.9 percentage points below the California state rate of 29.1%. Diagnosed diabetes reaches 7.3% of adults in Redondo Beach. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 14.6% of adults in Redondo Beach.

of Redondo Beach adults have obesity
21.2%
diagnosed diabetes
7.3%
no regular physical activity
14.6%

Age-adjusted estimates for Redondo Beach, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossOzempic side effects in men
§ 05Support around Wegovy in Redondo Beach
6 dietitians

The prescription is one part. Here is the rest, in Redondo Beach.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Redondo Beach, CA, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Alyssa Baldino, RD
RD
Registered dietitian
219 S Irena Ave # 1
Call 609-468-8851NPI 1447702949
Stanley Cachola, RD
RD
Registered dietitian
1703 Mackay Ln # B
Call 310-910-4737NPI 1932400157
Kimberly Cahill, RD
RD
Registered dietitian
710 N Juanita Ave
Call 310-683-9362NPI 1093779035
Lori Chang
RD
Registered dietitian
5105 W Goldleaf Cir
Call 323-298-3300NPI 1699208330
Winy Chen, MS RD
RD
Registered dietitian
506 S Maria Ave
Call 310-721-5280NPI 1730205360
Kristina Cooke, RD
RD
Registered dietitian
500 Avenue G Apt 10
Call 424-348-0475NPI 1245894906

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Tommy Comer, Nutritionist
NUTRITIONIST
Nutritionist
1907 Nelson Ave
Call 925-984-4263NPI 1417654674
Rande Freedman, NC
NUTRITIONIST
Nutritionist · Education
609 Meyer Ln Unit 19
Call 310-318-1356NPI 1922476340
Juli Keene, CN
NUTRITIONIST
Nutritionist
1603 Aviation Blvd
Call 310-503-0592NPI 1578870473
Phyllis Tindall
NUTRITIONIST
Nutritionist
1926 S Pacific Coast Hwy Ste 203
Call 310-210-8233NPI 1679782288
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize results from the STEP program, the global Phase IIIa trials Novo Nordisk submitted to the FDA for the weight-management indication, and the SELECT cardiovascular outcomes trial. Numbers below are means at the 68-week endpoint, 2.4 mg weekly dose.

STEP-1 randomized 1,961 adults with obesity to weekly 2.4 mg semaglutide vs placebo over 68 weeks. Mean body-weight reduction was 14.9% on semaglutide vs 2.4% on placebo. 86.4% of patients on semaglutide achieved ≥ 5% weight loss vs 31.5% on placebo.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
Weight change
−14.9%
vs −2.4% placebo, 68 wk[4]
≥ 5% weight loss
86.4%
vs 31.5% placebo[4]
≥ 15% weight loss
50.5%
vs 4.9% placebo[4]
Major adverse cardiac events
−20%
HR 0.80 vs. placebo (SELECT)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Wegovy weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
44%
mild
More common than at Ozempic doses; usually transient and dose-dependent
Diarrhea
30%
mild
Most frequent during dose escalation phase
Vomiting
24%
mild
Slower titration reduces incidence
Constipation
24%
mild
Hydration + fiber recommended
Abdominal pain
20%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; class warning
Gallbladder disease
1.6%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$1,300 to $1,500
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $400
per month copay
Varies by PBM; many plans require BMI ≥ 30 + step therapy
Commercial insurance (denied)
Typically denied
Most plans exclude weight-loss medications from formulary
Medicare Part D
Not covered
Statutory exclusion of weight-loss drugs in original Medicare[5]
Manufacturer savings card
as low as $0
per month for 12 mo
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Wegovy providers in California

NPI-verified Wegovy (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Wegovy in other states

Find NPI-verified Wegovy (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Wegovy in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

FDA approval is for adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Adolescents 12+ with a BMI in the 95th percentile or higher were added to the label in December 2022.[1]